Related references
Note: Only part of the references are listed.Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments
Ian F. Tannock et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC
Yasuto Yoneshima et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer
Takeru Kashiwada et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease
Yuichiro Yasuda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease
Yuto Yasuda et al.
MOLECULAR AND CLINICAL ONCOLOGY (2017)
Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease
Hideyuki Niwa et al.
MOLECULAR AND CLINICAL ONCOLOGY (2017)
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial
Kohei Shitara et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors
Kazuhiko Yamada et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer
Yuichiro Ohe et al.
CLINICAL CANCER RESEARCH (2008)
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer
Naiyer A. Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer
A Inoue et al.
LUNG CANCER (2006)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel
N Desai et al.
CLINICAL CANCER RESEARCH (2006)
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies
DW Nyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Relevance of high-dose chemotherapy in solid tumours
P Nieboer et al.
CANCER TREATMENT REVIEWS (2005)
Share Paper
